[Pollinosis therapy with Galphimia glauca].
Until now the therapy of pollinosis with Galphimia glauca was based on individual experience. We performed a randomized, controlled, multicenter, and double-blind clinical trial to verify the effectiveness of the Galphimia glauca D4 therapy of patients with pollinosis. The average time of observation was 51/2 weeks. Galphimia was found to be more effective than placebo at a 1% level of significance. Therapeutic success was given in 34/41 (= 83%) of the patients with Galphimia and in 21/45 (= 47%) of the control patients.
D000293:Adolescent; D000328:Adult; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D031582:Galphimia; D006801:Humans; D008297:Male; D010936:Plant Extracts / Q000627:therapeutic use*; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy*
C036872:Galphimia glauca extract; D010936:Plant Extracts
Pollinosis-Therapie mit Galphimia glauca.